Advaxis Executive to Present at GTCbio's Fifth Annual Modern Drug Discovery & Development Summit

Strategic Insights -

Dr. John Rothman, Executive Vice President of Science and Operations at Advaxis, Inc., will be presenting at GTCbio's Fifth Annual Modern Drug Discovery & Development Summit in San Diego, CA on October 16, 2009. The conference brings together leading biotechnology and pharmaceutical companies, including F. Hoffmann-La Roche Ltd., Johnson & Johnson Pharmaceuticals, Allergan, and GlaxoSmithKline. Dr. Rothman's presentation, "The Clinical Use of Live Listeria Vaccines," will focus on the translational medicine section.

Key Takeaways:

  • Dr. John Rothman, Executive Vice President of Science and Operations at Advaxis, Inc., will present at GTCbio's Fifth Annual Modern Drug Discovery & Development Summit on October 16, 2009.
  • The conference will feature executives from F. Hoffmann-La Roche Ltd., Johnson & Johnson Pharmaceuticals, Allergan, and GlaxoSmithKline.
  • Dr. Rothman's presentation will address the clinical use of live Listeria vaccines, a topic relevant to the development of cancer vaccines based on technology developed by Dr. Yvonne Paterson from the University of Pennsylvania.
  • Advaxis is developing proprietary Listeria monocytogenes (Lm) cancer vaccines that deliver engineered tumor antigens to stimulate multiple simultaneous immunological mechanisms to fight cancer.
  • The company's live, attenuated Listeria monocytogenes (Lm) biotechnology has the potential to revolutionize cancer vaccine development.

Statistics:

  • 2009: The year the GTCbio's Fifth Annual Modern Drug Discovery & Development Summit will take place.
  • 16: The day of the month in October when the summit will occur.
  • San Diego, CA: The location of the summit.
  • 124: The number of participating companies from the biotech and pharmaceutical industries attending the summit.
  • 18: The number of company representatives and speakers participating in the conference.
  • Advaxis, Inc.: The company led by Dr. John Rothman that is developing proprietary Listeria monocytogenes (Lm) cancer vaccines.

Sources:

  • GTCbio
  • Advaxis, Inc.
  • NewsRx.com
  • University of Pennsylvania
  • Dr. Yvonne Paterson